Zepbound and sleep apnea: how it works and who it is for

What this guide covers

Zepbound is the first drug FDA-approved for obstructive sleep apnea in adults with obesity. Here is how a weight medication came to treat a breathing disorder, what the trial showed, and what it does not replace. This is patient education, not a substitute for the prescriber who knows your case. Generic names sit next to brand names throughout: semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound).

Key points

• A first-of-its-kind approval. In late 2024 the FDA approved Zepbound (tirzepatide) for moderate-to-severe obstructive sleep apnea in adults who also have obesity, making it the first medication ever approved to treat this breathing disorder. Until then, obstructive sleep apnea was managed with devices like CPAP, oral appliances, weight loss, and sometimes surgery, but not with a drug. The approval does not make Zepbound a stand-alone cure; it adds a medication option for a specific group, used alongside a reduced-calorie diet and more activity.
• Why a weight drug helps a breathing problem. Obstructive sleep apnea happens when the airway repeatedly collapses during sleep, and excess weight around the neck and upper airway, plus fat around the abdomen that limits how fully the lungs expand, is a major driver in many people. Because Zepbound reduces body weight, it can reduce the mechanical load on the airway, which lessens how often breathing is interrupted. So it is not acting on the lungs directly; it is treating a root contributor, the excess weight, which in turn eases the apnea for people whose apnea is weight-related.
• What the trial showed. The approval rested on the SURMOUNT-OSA trials, which measured the apnea-hypopnea index, the number of breathing interruptions per hour of sleep. People on tirzepatide had a substantially larger drop in that index than those on placebo, both those using CPAP and those not, and many also saw improvements in weight and related measures. The result was strong enough that regulators judged it a meaningful treatment effect for this population, which is what earned the specific sleep-apnea indication rather than an off-label use.
• What it does not replace. Zepbound is not a replacement for CPAP or a diagnosis. Sleep apnea needs to be diagnosed with a proper sleep study, and CPAP remains a first-line, highly effective therapy that works from the first night, whereas a medication works gradually as weight changes. For some people the combination is the plan; for others the medication may reduce severity over time. None of that is a decision to make alone. It requires a sleep specialist or prescriber who can test, monitor, and decide what fits.
• The usual caveats still apply. Being approved for sleep apnea does not change Zepbound's side-effect profile or warnings. The same gut side effects, the same thyroid-tumor boxed warning, and the same cautions around pancreatitis, gallbladder problems, and dehydration all carry over. It is also still a tirzepatide product with the birth-control interaction note. The sleep-apnea approval simply means there is now trial evidence and a formal indication for using it in this group, under the same overall safety framework as its weight-management use.

Frequently asked questions